Ocular Therapeutix reported a phase 3 win that it believes can validate its attempts to challenge Regeneron’s entrenched ...

New research highlights progress in treating age-related macular degeneration, including late‑stage drug trials, gene therapy strategies, and a wireless retinal prosthesis that restored limited ...

Following the successful late-stage study in wet age-related macular degeneration, Ocular plans to meet with the FDA to ...

Researchers reviewed the phase 3 findings of a TKI inhibitor treatment compared with aflibercept 2 mg for maintaining vision in patients with wet AMD.

In a phase 3 trial, Axpaxli, a tyrosine kinase inhibitor, achieved its superiority primary endpoint vs. aflibercept for the ...

The company is set to release topline results from its Phase 3 superiority trial of Axpaxli in wet AMD on Tuesday. ・Ocular ...

Ocular Therapeutix has released positive topline results from SOL-1, its phase 3 superiority trial of AXPAXLI for the ...

First ever successful demonstration of superiority in an FDA-aligned wet AMD trial comparing a novel investigative agent to an approved anti-VEGF ...

Eylea HD injected every 12 or 16 weeks controls neovascular age-related macular degeneration to a similar extent as Eylea ...

Apps may be available on your phone to help you monitor your wet AMD symptoms and assist you with everyday tasks such as reading, texting, and identifying objects. Advanced neovascular age-related ...

Ocular to host webcast scheduled for Tuesday, February 17, 2026, at 8:00 AM ETDetailed SOL-1 data to be presented at the 49th Macula Society ...